Despite the proliferation of
technologies to derive induced pluripotent stem cells since they were first
described five years ago, this has been a technology in search of a home. The
tide may have finally turned. In March, Cellular Dynamics International Inc. said
its induced pluripotent stem cell-derived product-iCell Cardiomyocytes-will
be added to the drug development toolbox at Roche.
Lou, K.-J. SciBX 4(21); doi:10.1038/scibx.2011.588
Published online May 26, 2011
1. Takahashi, K. & Yamanaka, S. Cell 126,
2. Warren, L. et al. Cell Stem Cell 7,
3. Wu, S.M. & Hochedlinger, K. Nat. Cell Biol.
13, 497-505 (2011)
4. Gore, A. et al. Nature 471, 63-67
5. Laurent, L.C. et al. Cell Stem Cell 8,
6. Hussein, S.M. et al. Nature 471,
7. Zhao, T. et al. Nature; published
online May 13, 2011; doi:10.1038/nature10135 Contact: Yang Xu,
University of California, San Diego, La Jolla, Calif. e-mail: email@example.com
Astellas Pharma Inc.
(Tokyo:4503), Tokyo, Japan
Cellular Dynamics International Inc.,
Hospital Boston, Boston, Mass.
Fate Therapeutics Inc.,
San Diego, Calif.
Gladstone Institute of Cardiovascular
Disease, San Francisco, Calif.
(LSE:GSK; NYSE:GSK), London, U.K.
Harvard Stem Cell Institute,
South San Francisco, Calif.
(NYSE:NVS; SIX:NOVN), Basel, Switzerland
(NYSE:PFE), New York, N.Y.
(SIX:ROG; OTCQX:RHHBY), Basel, Switzerland
(Euronext:SAN; NYSE:SNY), Paris, France
(NASDAQ:STEM), Palo Alto, Calif.
Takeda Pharmaceutical Co. Ltd.
(Tokyo:4502), Osaka, Japan
University of California, San Diego,
La Jolla, Calif.
University of California, San Francisco,